Please login to the form below

Not currently logged in

European regulator wants Abbott's Loftyl suspended

EMA says risk of serious cardiological and neurological side effects of peripheral arterial occlusive disease treatment too great

The European Medicines Agency (EMA) has recommended the suspension of Abbott's Loftyl (buflomedil) due to the risk of serious cardiological and neurological side effects.

The regulator said that any potential benefits of buflomedil, which is used to treat peripheral arterial occlusive disease, did not outweigh its risks.

A review by the EMA's Committee for Medicinal Products for Human Use (CHMP) concluded efforts to minimise these risks, including restricting its use in certain patients, had not been able to cut down buflomedil's potential for harm.

Data supporting the benefits of the agent, which has been authorised in the EU since the 1970s, was also said to be 'limited and of poor quality'.

The EMA's review of buflomedil was initiated following France's decision to suspend Loftyl's marketing authorisation in February, 2011.

Doctors are now advised to stop using buflomedil in favour of other treatment options, while patients on the drug should speak to their healthcare professional.

The CHMP's recommendation to suspend medicines containing buflomedil, including Abbott's Loftyl, will be discussed by the European Commission which will make a final decision on the drug's marketing authorisation.

18th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...